Table 3.
In vitro activity of ceftolozane–tazobactam and comparators against 673 isolates from Brazil.
| Organism (n) | Antimicrobial | %S | %I | %R | MIC 50 | MIC90 | Range |
|---|---|---|---|---|---|---|---|
| Pseudomonas aeruginosa (132) | Ceftolozane–tazobactam | 84.9 | 4.6 | 10.6 | 1 | 16 | 0.5–>32 |
| Amikacin | 84.9 | 3.0 | 12.1 | ≤4 | >32 | ≤4–>32 | |
| Aztreonam | 50.0 | 15.9 | 34.1 | 8 | >16 | 2–>16 | |
| Cefepime | 61.4 | 12.9 | 25.8 | 8 | >32 | ≤1–>32 | |
| Ceftazidime | 59.9 | 9.9 | 30.3 | 8 | >32 | ≤1–>32 | |
| Ciprofloxacin | 68.9 | 6.8 | 24.2 | ≤0.25 | >2 | ≤0.25–>2 | |
| Colistin | 99.2 | – | 0.8 | ≤1 | ≤1 | ≤1–4 | |
| Imipenem | 53.0 | 6.1 | 40.9 | 2 | 32 | ≤0.5–>32 | |
| Levofloxacin | 62.9 | 7.6 | 29.6 | ≤1 | >4 | ≤1–>4 | |
| Meropenem | 58.3 | 9.9 | 31.8 | 2 | >16 | ≤0.12–>16 | |
| Piperacillin-tazobactam | 55.3 | 14.4 | 30.3 | 16 | >64 | ≤2–>64 | |
| Escherichia coli (216) | Ceftolozane–tazobactam | 94.9 | 2.3 | 2.8 | 0.25 | 1 | ≤0.06–>32 |
| Amikacin | 97.7 | 0.9 | 1.4 | ≤4 | 8 | ≤4–>32 | |
| Aztreonam | 67.1 | 7.4 | 25.5 | ≤1 | >16 | ≤1–>16 | |
| Cefepime | 65.3 | 7.9 | 26.9 | ≤1 | >32 | ≤1–>32 | |
| Cefotaxime | 60.7 | 1.4 | 38.0 | ≤1 | >32 | ≤1–>32 | |
| Cefoxitin | 68.5 | 14.8 | 16.7 | 8 | >16 | ≤2–>16 | |
| Ceftazidime | 70.4 | 9.7 | 19.9 | ≤1 | 16 | ≤1–>32 | |
| Ceftriaxone | 59.7 | 1.4 | 38.9 | ≤1 | >32 | ≤1–>32 | |
| Ciprofloxacin | 47.7 | 1.9 | 50.5 | >2 | >2 | ≤0.25–>2 | |
| Colistin | 98.2 | – | 1.9 | ≤1 | ≤1 | ≤1–4 | |
| Ertapenem | 94.0 | 0.5 | 5.6 | ≤0.06 | 0.12 | ≤0.06–>4 | |
| Imipenem | 97.2 | 1.9 | 0.9 | ≤0.5 | ≤0.5 | ≤0.5–8 | |
| Levofloxacin | 49.5 | 3.7 | 46.8 | 4 | >4 | ≤1–>4 | |
| Meropenem | 97.2 | 1.4 | 1.4 | ≤0.12 | ≤0.12 | ≤0.12–>16 | |
| Piperacillin-tazobactam | 91.7 | 3.7 | 4.6 | ≤2 | 16 | ≤2–>64 | |
| Klebsiella pneumoniae (193) | Ceftolozane–tazobactam | 40.4 | 3.6 | 56.0 | 16 | >32 | 0.25–>32 |
| Amikacin | 91.2 | 1.6 | 7.3 | ≤4 | 16 | ≤4–>32 | |
| Aztreonam | 23.8 | 3.1 | 73.1 | >16 | >16 | ≤1–>16 | |
| Cefepime | 25.4 | 7.8 | 66.8 | >32 | >32 | ≤1–>32 | |
| Cefotaxime | 21.8 | 2.1 | 76.2 | >32 | >32 | ≤1–>32 | |
| Cefoxitin | 39.9 | 10.4 | 49.7 | 16 | >16 | ≤2–>16 | |
| Ceftazidime | 28.5 | 2.1 | 69.4 | >32 | >32 | ≤1–>32 | |
| Ceftriaxone | 20.7 | 1.6 | 77.7 | >32 | >32 | ≤1–>32 | |
| Ciprofloxacin | 25.9 | 2.1 | 72.0 | >2 | >2 | ≤0.25–>2 | |
| Colistin | 90.2 | – | 9.8 | ≤1 | 2 | ≤1–>4 | |
| Ertapenem | 53.4 | 1.0 | 45.6 | 0.5 | >4 | ≤0.06–>4 | |
| Imipenem | 61.1 | 4.7 | 34.2 | ≤0.5 | 32 | ≤0.5–>32 | |
| Levofloxacin | 28.5 | 4.7 | 66.8 | >4 | >4 | ≤1–>4 | |
| Meropenem | 60.1 | 2.1 | 37.8 | ≤0.12 | >16 | ≤0.12–>16 | |
| Piperacillin-tazobactam | 30.6 | 14.0 | 55.4 | >64 | >64 | ≤2–>64 | |
| Other Enterobacteralesa (132) | Ceftolozane–tazobactam | 81.1 | 3.0 | 15.9 | 0.5 | 16 | 0.12–>32 |
| Amikacin | 90.9 | 2.3 | 6.8 | ≤4 | 16 | ≤4–>32 | |
| Aztreonam | 72.0 | 0.8 | 27.3 | ≤1 | >16 | ≤1–>16 | |
| Cefepime | 62.1 | 10.6 | 27.3 | ≤1 | >32 | ≤1–>32 | |
| Cefotaxime | 52.3 | 3.0 | 44.7 | ≤1 | >32 | ≤1–>32 | |
| Cefoxitin | 56.1 | 6.1 | 37.9 | 8 | >16 | ≤2–>16 | |
| Ceftazidime | 72.7 | 2.3 | 25.0 | ≤1 | >32 | ≤1–>32 | |
| Ceftriaxone | 52.3 | 5.3 | 42.4 | ≤1 | >32 | ≤1–>32 | |
| Ciprofloxacin | 63.6 | 2.3 | 34.1 | ≤0.25 | >2 | ≤0.25–>2 | |
| Colistin | 40.9 | – | 59.1 | >4 | >4 | ≤1–>4 | |
| Ertapenem | 88.6 | 3.8 | 7.6 | ≤0.06 | 1 | ≤0.06–>4 | |
| Imipenem | 72.0 | 18.9 | 9.1 | ≤0.5 | 2 | ≤0.5–>32 | |
| Levofloxacin | 68.9 | 4.6 | 26.5 | ≤1 | >4 | ≤1–>4 | |
| Meropenem | 93.9 | 0 | 6.1 | ≤0.12 | 0.25 | ≤0.12–>16 | |
| Piperacillin-tazobactam | 80.3 | 7.6 | 12.1 | ≤2 | >64 | ≤2–>64 |
%S, I, R: percent susceptible, intermediate, resistant by CLSI 2017 guidelines, EUCAST guidelines for colistin were applied for Enterobacterales; MIC50, MIC90, and range in μg/mL; –, no intermediate breakpoint.
a
Other Enterobacterales consist of (n): Klebsiella aerogenes (3); Enterobacter asburiae (1); E. cloacae (38); Klebsiella oxytoca (11); K. variicola (4); Morganella morganii (1); Proteus mirabilis (72); P. vulgaris (1); Providencia rettgeri (1).